相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。AMP-224, A FUSION PROTEIN THAT TARGETS PD-1
F. Smothers et al.
ANNALS OF ONCOLOGY (2013)
PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells
Erin E. West et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Continued Response Off Treatment After BRAF Inhibition in Refractory Hairy Cell Leukemia
Sascha Dietrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Results of a Randomized Trial of Chlorambucil Versus Fludarabine for Patients With Untreated Waldenstrom Macroglobulinemia, Marginal Zone Lymphoma, or Lymphoplasmacytic Lymphoma
Veronique Leblond et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
Omid Hamid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Critical Review of Preclinical Approaches to Investigate Cytochrome P450-Mediated Therapeutic Protein Drug-Drug Interactions and Recommendations for Best Practices: A White Paper
Raymond Evers et al.
DRUG METABOLISM AND DISPOSITION (2013)
Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
Seng-Ryong Woo et al.
CANCER RESEARCH (2012)
Lung Cancer: A Classic Example of Tumor Escape and Progression While Providing Opportunities for Immunological Intervention
Martin R. Jadus et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2012)
Programmed Death Ligand 2 in Cancer-Induced Immune Suppression
Esdy N. Rozali et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2012)
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
State of the Science: An Update on Renal Cell Carcinoma
Eric Jonasch et al.
MOLECULAR CANCER RESEARCH (2012)
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
Julian R. Molina et al.
MAYO CLINIC PROCEEDINGS (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Immunological response as a source to variability in drug metabolism and transport
Hege Christensen et al.
FRONTIERS IN PHARMACOLOGY (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms
Mikayel Mkrtichyan et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2011)
PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine
Jacalyn Rosenblatt et al.
JOURNAL OF IMMUNOTHERAPY (2011)
The potential for crizotinib in non-small cell lung cancer: a perspective review
Yung-Jue Bang
Therapeutic Advances in Medical Oncology (2011)
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
Don M. Benson et al.
BLOOD (2010)
Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer
Yan Zhang et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2010)
CYP-Mediated Therapeutic Protein-Drug Interactions Clinical Findings, Proposed Mechanisms and Regulatory Implications
Jang-Ik Lee et al.
CLINICAL PHARMACOKINETICS (2010)
Blockade of Programmed Death-1 Pathway Rescues the Effector Function of Tumor-Infiltrating T Cells and Enhances the Antitumor Efficacy of Lentivector Immunization
Qifeng Zhou et al.
JOURNAL OF IMMUNOLOGY (2010)
Enhanced Tumor Eradication by Combining CTLA-4 or PD-1 Blockade With CpG Therapy
Sara M. Mangsbo et al.
JOURNAL OF IMMUNOTHERAPY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
Michael A. Curran et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Tumor-Expressed B7-H1 and B7-DC in Relation to PD-1+T-Cell Infiltration and Survival of Patients with Cervical Carcinoma
Rezaul Karim et al.
CLINICAL CANCER RESEARCH (2009)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
Anti-Programmed Death-1 Synergizes with Granulocyte Macrophage Colony-Stimulating Factor-Secreting Tumor Cell Immunotherapy Providing Therapeutic Benefit to Mice with Established Tumors
Betty Li et al.
CLINICAL CANCER RESEARCH (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4(+)CD25(Hi) regulatory T cells
Wenshi Wang et al.
INTERNATIONAL IMMUNOLOGY (2009)
PD-1 and its ligands in tolerance and immunity
Mary E. Keir et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies
Raanan Berger et al.
CLINICAL CANCER RESEARCH (2008)
Inhibitory B7-family molecules in the tumour microenvironment
Weiping Zou et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs
Raymond M. Wong et al.
INTERNATIONAL IMMUNOLOGY (2007)
Targeting molecular and cellular inhibitory mechanisms for improvement of antitumor memory responses reactivated by tumor cell vaccine
W. Scott Webster et al.
JOURNAL OF IMMUNOLOGY (2007)
Review: Anti-CTLA-4 antibody ipilimumab: Case studies of clinical response and immune-related adverse events
Jeffrey Weber
ONCOLOGIST (2007)
Biochemical Mechanisms of Cisplatin Cytotoxicity
Victoria Cepeda et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2007)
Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer
Takeo Nomi et al.
CLINICAL CANCER RESEARCH (2007)
Cancer despite immunosurveillance: immunoselection and immunosubversion
Laurence Zitvogel et al.
NATURE REVIEWS IMMUNOLOGY (2006)
Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro
C Blank et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Erlotinib in previously treated non-small-cell lung cancer
FA Shepherd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Epidermal growth factor receptor mutations in non-small-cell lung cancer:: Implications for treatment and tumor biology
PA Jänne et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells
Y Iwai et al.
INTERNATIONAL IMMUNOLOGY (2005)
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
TJ Curiel et al.
NATURE MEDICINE (2003)
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Y Iwai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
分享论文
